Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
reconstitution and storage technique Specific Bottlenecks Plateau at weeks 46
Goal: Support skin remodeling, collagen/elastin synthesis and tissue repair via the copper tripeptide effects reported mainly from topical, in-vitro and animal work, not established in humans by injection [3] [5]
imports of gray-market peptides and hormones from China roughly doubled last year
Why Continuous Use Makes More Sense Metabolically Fat loss is a slow biological process
At Elase, all therapies are prescribed and monitored under medical supervision